Form 4: Director Candace Duncan Receives Teleflex Equity Grant

Teleflex Incorporated Director Candace H. Duncan was granted 1,090 restricted stock units and 2,397 stock options.

Summary

• Director Candace H. Duncan received an equity grant on May 15, 2026.
• The grant included 1,090 restricted stock units (RSUs) and 2,397 stock options.
• The stock options have an exercise price of $129.71 per share.
• Following this transaction, the director's total beneficial ownership of common stock is 7,039.3406 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on company operations or financial strategy.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standard retention and incentive structure for board members.

Negatives

• Dilutive impact of new equity grants on existing shareholders, though minimal in scale.

Risks

• Market price volatility affecting the value of the granted options and RSUs.

Future Outlook

The equity awards vest on the one-year anniversary of the grant date, or earlier if the director does not stand for re-election at the 2027 Annual Meeting, subject to specific timing conditions.

Management Comments

• The grants were issued pursuant to the Teleflex Incorporated 2023 Stock Incentive Plan.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the medical device industry to ensure long-term alignment with shareholder value creation.

Comparison to Industry Standards

• The use of a mix of RSUs and stock options is consistent with compensation practices at peer medical technology companies like Medtronic and Edwards Lifesciences.
• Vesting schedules tied to annual meeting cycles are standard for board-level compensation.

Stakeholder Impact

• Minimal impact on shareholders due to the small size of the equity grant relative to total shares outstanding.

Next Steps

• Vesting of restricted stock units on May 15, 2027.
• Vesting of stock options on May 15, 2027.

Key Dates

Keywords

Teleflex, TFX, Form 4, Director Compensation, Insider Transaction, Equity Grant